Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series일본 코로나19 관련 급성호흡곤란증후군에 의한 사이토카인 분비 증후군 환자에서 인터루킨 6 억제제 토실리주맙의 사용 증례 시리즈Article Published on 2020-11-012022-09-12 Journal: Respiratory investigation [Category] 진단, [키워드] acute respiratory distress case sery caused Cytokine release syndrome inhibitor Japanese Patient Tocilizumab [DOI] 10.1016/j.resinv.2020.09.006 PMC 바로가기 [Article Type] Article
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trialResearch article Published on 2020-11-012022-10-05 Journal: International immunopharmacology [Category] SARS, 임상, [키워드] Activation acute respiratory distress Administered Adverse drug reactions adverse effect analyzed C-reactive protein changes in Clinical improvement coronavirus COVID-19 Critical death dose Effect eligibility evaluate the effect evaluated IL-6 IL-6 antagonist inflammatory cascade Inflammatory cytokine initiated interleukin 6 intravenous Invasive mechanical ventilation invasive ventilation Lungs median age Mild symptom outcome Oxygenation Patient patients patients died plasma predominant Prospective clinical trial radiological released required Result SARS-CoV-2 SARS-COV-2 infection secondary severe complications Severe infection single dose SPSS software Support syndrome the median Tocilizumab tocilizumab administration [DOI] 10.1016/j.intimp.2020.106869 [Article Type] Research article
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumabObservational Study Published on 2020-11-012023-07-12 Journal: Journal of autoimmunity [Category] SARS, [키워드] COVID-19 Critical illness Cytokine release syndrome interleukin-6 severe acute respiratory syndrome coronavirus 2 Tocilizumab [DOI] 10.1016/j.jaut.2020.102512 PMC 바로가기 [Article Type] Observational Study
Tocilizumab in patients with severe COVID-19: A single-center observational analysis중증 코로나19 환자의 토실리주맙: 단일 센터 관찰 분석Observational Study Published on 2020-11-012022-09-12 Journal: Journal of medical virology [Category] 임상, 진단, [키워드] Admission Analysis baseline benefit changes in clinical Clinical improvement common Comorbidity coronavirus disease COVID-19 CRP cytokine cytokine release Cytokine release syndrome Cytokine storm decrease develop Diabetes Mellitus diagnosed with COVID-19 died discharged disease severity dose elevated evaluate evaluated expired glucocorticoid hospital Hydroxychloroquine hypertension IL-6 IL-6 antagonist interleukin-6 receptor marker Mortality Most patient oxygen-support oxygenation status Patient patient population proinflammatory Protein reported retrospective severe COVID-19 Severe respiratory distress single-center Support thought Tocilizumab transferred Treatment Trial Ventilation worsened [DOI] 10.1002/jmv.26191 PMC 바로가기 [Article Type] Observational Study
Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6토실리주맙 이후 초기에 높은 수준의 IL-6은 COVID-19 폐렴에서 생존자와 비생존자를 구별합니다: IL-6의 더 깊은 표적화에 대한 가능한 징후Article Published on 2020-11-012022-09-11 Journal: Journal of medical virology [Category] 바이오마커, 진단, [키워드] 48 hour 48 hours 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected All the patient all the patients baseline blocking cause choice Comparisons coronavirus COVID-19 COVID-19 patients COVID-19 pneumonia cytokine cytokine release storm Cytokine storm discharged dose elevated get out hyperinflammatory state IL-6 interleukin interleukin-6 intravenously Laboratory material nonsurvivor nonsurvivors not different outcomes Patient patients died performed Pneumonia Predictive respiratory serious COVID-19 serum Serum IL-6 Serum level serum levels severe acute respiratory syndrome Coronavirus significantly significantly higher Support survivor tested the cytokine storm Tocilizumab two group two groups [DOI] 10.1002/jmv.26149 PMC 바로가기 [Article Type] Article
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review토실리주맙으로 치료한 코로나19 환자의 임상 결과: 개별 환자 데이터 체계적 검토Article Published on 2020-11-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] acute respiratory distress acute respiratory syndrome added analyzed anti-IL-6 anti-interleukin-6 receptor antibody average baseline baseline characteristics C-reactive protein (CRP Case report cause changes in Characteristics clinical Clinical outcome clinical outcomes Comorbidity coronavirus coronavirus disease COVID-19 COVID-19 patient CRP level current cytokine release storm Cytokine storm decrease demographics elevated Endpoint Evidence Fisher hospital hyperinflammatory state hypertension IL-6 IL-6 level IL-6 pathway in-hospital complications in-hospital mortality inclusion criteria individual level individual patient data inflammatory markers inhibition interleukin-6 interquartile range knowledge Laboratory male median nonsurvivor not significantly different observational study occurred outcome over pathway Patient patient data patients performed primary endpoint Primary outcome randomized control trial recent receptor reported SARS-CoV-2 secondary severe COVID-19 significantly significantly higher Standard deviation surviving patients survivor syndrome systematic review the primary endpoint therapy Tocilizumab treated Treatment worsened disease [DOI] 10.1002/jmv.26038 PMC 바로가기 [Article Type] Article
Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2SARS-CoV-2로 인한 초기 ARDS가 있는 고형 및 복합 조직 이식 수혜자 5명에 대한 토실리주맙 요법Case Reports Published on 2020-11-012022-09-12 Journal: American journal of transplantation : official jou [Category] SARS, 진단, [키워드] acute respiratory distress acute respiratory syndrome ARDS Bacterial infection characterized chimeric antigen receptor Clinical course Clinical management clinical research/practice clinical utility condition coronavirus coronavirus disease Course COVID-19 CRP cytokine Cytokine release syndrome data-driven described dysregulated immune response elevated Guidance high mortality IL-6 IL-6 receptor Infection infection and infectious agents - viral infectious agent Infectious disease Inflammatory response involved occurred off-label off-label drug use. organ outcome Oxygenation Protein Randomized recipient reductions in reported Respiratory mechanics response SARS-CoV-2 solid organ transplant Support syndrome T-cell therapeutic agent therapy tissue Tocilizumab tocilizumab administration Trial variety vasopressors ventilator [DOI] 10.1111/ajt.16080 PMC 바로가기 [Article Type] Case Reports
Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with Coronavirus Disease 2019 in New York City뉴욕시에서 코로나바이러스 질병 2019를 앓고 있는 중환자 및 청소년의 임상 징후 및 결과Observational Study Published on 2020-11-012022-09-11 Journal: The Journal of pediatrics [Category] 임상, 치료제, [키워드] Acute kidney injury acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome Adolescent Anakinra ARDS Cardiac arrest children children with COVID-19 clinical clinical manifestation clinical manifestations Comorbidities convalescent plasma coronavirus coronavirus disease Coronavirus disease-19 Corticosteroids cough COVID-19 Critically ill extracorporeal membrane oxygenation Hispanic hospital hospital discharge Hospital stay Hydroxychloroquine Ill Immunoglobulin IMV Infection Inhaled intensive care unit Invasive mechanical ventilation IQR manifestation mechanical ventilation median median age New York City nitric oxide noninvasive observational study outcome Patient pediatric pediatric ARDS pediatric respiratory failure pediatric viral sepsis. Presence presenting symptoms Probability Prone position Remdesivir required respiratory respiratory distress Respiratory failure Respiratory Support Sepsis severe acute respiratory syndrome Coronavirus severe sepsis significantly syndrome therapy Tocilizumab Treatment vasopressor support Viral [DOI] 10.1016/j.jpeds.2020.07.039 PMC 바로가기 [Article Type] Observational Study
COVID-19 in lung transplant recipients: A single center case series from New York City폐 이식 환자의 COVID-19: 뉴욕시의 단일 센터 사례 시리즈Article Published on 2020-11-012022-09-11 Journal: American journal of transplantation : official jou [Category] SARS, 진단, 치료제, [키워드] Acute kidney injury acute respiratory distress acute respiratory distress syndrome Admission arrhythmia Arrhythmias Azithromycin blood cell C-reactive protein case sery Complication cough COVID-19 D-dimer died during admission Dyspnea event Fever followed by high mortality rate Hydroxychloroquine lung transplant lymphocyte Lymphocyte count median age median time Mild moderate Moderate COVID-19 neurological New York City Patient patients with moderate performed positive recipients Remdesivir respiratory distress retrospective SARS-CoV-2 severe COVID-19 Shock single center steroid Steroids syndrome tested the median Tocilizumab transaminitis Transplant Venous Thromboembolism White blood cell [DOI] 10.1111/ajt.16241 PMC 바로가기 [Article Type] Article
Use of tocilizumab in kidney transplant recipients with COVID-19COVID-19가 있는 신장 이식 수혜자의 토실리주맙 사용Multicenter Study Published on 2020-11-012022-09-12 Journal: American journal of transplantation : official jou [Category] MERS, SARS, 진단, [키워드] Admission Analysis C-reactive protein (CRP clinical research/practice coronavirus disease Coronavirus infection COVID-19 CRP Cytokine storm D-dimer death decrease died distress effective ferritin hazard ratio high-risk population Hospital admission Host immune response IL-6 increased the risk Infection infection and infectious agents - viral infectious agent inflammatory markers interleukin-6 kidney kidney transplant kidney transplant recipient kidney transplantation/nephrology lactic acid dehydrogenase mortality rate multicenter cohort study nonsurvivors not significantly different Older Older age outcome outcomes pandemic Patient patient survival positively correlated randomized trial recipient severe COVID-19 Severe infection survival survivor syndrome Tocilizumab tocilizumab administration treated with COVID-19 [DOI] 10.1111/ajt.16192 PMC 바로가기 [Article Type] Multicenter Study